However, the absence of HRD in ATM-associated tumours does not exclude the possibility that HetAT subjects who develop BC may be sensitive to cisplatin and/or poly(ADP)-ribose polymerase (PARP) inhibitors, as reported by others for HetAT subjects who developed prostate cancer [50]. The gene discussed is ATM; the disease is Familial prostate cancer.